A Study of the Safety and Use of Tecfidera in Routine Medical Practice for the Treatment of Multiple Sclerosis


About this study

The purpose of this study is to better identify the long term benefit to risk profile of tecfidera in patients with multiple sclerosis who are prescribed tecfidera under routine clinical care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Have multiple sclerosis (MS)
  • Are newly initiating treatment with tecfidera (dimethyl fumarate) under routine clinical care
  • Other protocol defined inclusion criteria may apply


Exclusion Criteria

  • Previous exposure to dimethyl fumarate (DMF), fumaderm (fumaric acid esters), or compounded fumarates
  • Are participating in other clinical studies 
  • Other protocol defined exclusion criteria may apply

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

La Crosse, Wis.

Mayo Clinic principal investigator

Gregory Pupillo, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer